Oral Contraception and Breast Diseases
American Journal of Nursing Science
Volume 1, Issue 1, December 2012, Pages: 1-4
Received: Dec. 26, 2012; Published: Dec. 30, 2012
Views 4915      Downloads 263
A. Carbonaro, Dept of Obst and Gyn University of Catania, Italy
L. Ciotta, Via Torre del Vescovo 2, Catania, Italy
M. Stracquadanio, American University of Beirut- Lebanon
C. Formuso, Dept of Obst and Gyn University of Catania, Italy
M. R. Giunta, Via Torre del Vescovo 2, Catania, Italy
A. D. Agati, American University of Beirut- Lebanon
V. Leanza, Dept of Obst and Gyn University of Catania, Italy
T. T. Giannone, Via Torre del Vescovo 2, Catania, Italy
Mayada Chammas, American University of Beirut- Lebanon
Fawzi Chammas, Dept of Obst and Gyn University of Catania, Italy
C. Pafumi, Via Torre del Vescovo 2, Catania, Italy
G. Zarbo, American University of Beirut- Lebanon
Article Tools
Follow on us
Objective: Benign breast disease includes a wide spectrum of lesions different for histology and natural history, whose association with oral contraceptives is of great interest because there are no univocal results in literature. Subjects and Methods: The purpose of our study is to assess the relationship between women who used long- term estro-progestin (for at least 12 consecutive months up to a maximum of 60 months) and the develop of benign breast disease comparing with a case- control group composed by patients with benign breast disease, non-users of oral contraceptives. The study included 263 women attending, from 2009 to 2012, the Gynecological Endocrinology and Ultrasounds outpatients of our Department, who used oestroprogestative pills for Contraception, treatment of acne, hirsutism and treatment of dysmenorrheal and a control group of 200 patients with benign breast disease, non-users of Oral Contraceptives.Results: According to recent trials we did not observe statistically significant morphological and anatomical alterations of the breast in the group treated with estrogen-progestin therapy in comparison with the control group. Conclusion: If the woman presents a nodular breast mass during estro-progestin therapy she should be evaluated ultrasonographically to assess if the formation grows. If there is an increase in volume of the mass the patient should suspend the therapy.
Oral Contraception, Benign Breast Disease, Breast Cancer, Ultrasound Examination
To cite this article
A. Carbonaro, L. Ciotta, M. Stracquadanio, C. Formuso, M. R. Giunta, A. D. Agati, V. Leanza, T. T. Giannone, Mayada Chammas, Fawzi Chammas, C. Pafumi, G. Zarbo, Oral Contraception and Breast Diseases, American Journal of Nursing Science. Vol. 1, No. 1, 2012, pp. 1-4. doi: 10.11648/j.ajns.20120101.11
Pastides H., Kelsey JI, Livolsi VA et al.. Oral contraceptive use and fibrocystic breast disease with special reference to its histopathology. J Natl Cancer Inst. 1983 Jul;71(1):5-9.
Franceschi S., La Vecchia C., Parazzini F, Talamini R.. An epidemiological study on the relationship between oral contraceptives and benign breast disease. Contracept-fertil-sex. 14/2 (125-129). 1986.
Ragni N, Boccardo E, Viglino S, Larosa E. Oral contraception and breast pathology. Acta Eur Fertil. 1981 Jun;12(2):141-63.
Hsieh CC, Crosson AW, Walker AM, Trapido EJ, MacMahon B. Oral contraceptive use and fibrocystic breast disease of different histologic classifications. J Natl Cancer Inst. 1984 Feb;72(2):285-90.
Rohan TE, L'Abbé KA, Cook MG. Oral contraceptives and risk of benign proliferative epithelial disorders of the breast. Int J Cancer. 1992 Apr 1;50(6):891-4.
Ruan X, Seeger H, Mueck AO. Breast cancer risk during hormone therapy: experimental versus clinical data. Minerva Endocrinol. 2012 Mar;37(1):59-74.
Franchi F., Gioffrè WR, Calvelli P., et al.. Contraccezione orale e mastopatie benigne. Incontri di Endocrinologia Riproduttiva. 1994, Giu 5; 507-510.
Gadducci A, Guerrieri ME, Genazzani AR. Benign breast diseases, contraception and hormone replacement therapy. Minerva Ginecol. 2012 Feb;64(1):67-74.
Iatrakis G, Iavazzo C, Zervoudis S, Koumousidis A, Sofoudis C, Kalampokas T, Salakos N. The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients. Clin Exp Obstet Gynecol. 2011;38(3):225-7.
Veljković M, Veljković S. The risk of breast cervical, endometrial and ovarian cancer in oral contraceptive users. Med Pregl. 2010 Sep-Oct;63(9-10):657-61.
Geoffrey C.Kabat, Joan G.Jones, Neal Olson, Abdissa Negassa, Chaterine Duggan, Mindy Ginsberg, Rita A. Candel, Andrew G.Glass, Thomas E.Rohan. A multi-center prospective cohort srudy of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control, 2010 June; 21(6):821-828.
Hai-Lin Park, Sea-Hyun Kwon, So Yong Chang, Jung Yin Huh, Ji Young Kim, Jeong Yun Shim, Yoon Hee Lee. Long-Term Follow-up result of benign phyllode tumor of the breast diagnosed and excised by ultrasound-guided vacuum-assisted breast biopsy. J Breast Cancer, 2012 June 15(2):224-229.
Kròlik M, Milnerowicz H. The effect of using estrogens in the light of scientific research. Adv Clin Exp Med, 2012 Jul-Aug; 21(4):535-43.
Garad R, McNamee K, Bateson D, Harvey C. Update on contraception. Aust Nurs J, 2012 Oct, 20(4):34-7.
Rin Yamaguchi, Shin-ichi Tsuchiya, Takashi Koshikawa, Toshiro Yokoyama, Kuniko Mibuchi, Yasuhide Nonaka, Sonoe Ito, Hidejiro Higuchi, Mariko Nago, Koichi Higaki, Jiro Watanabe, Masayoshi Kage, Hirohisa Yano. Evaluation of inadequate, indeterminate, false-negative and false-positive cases in cytological examinationfor breast cancer according to histological type. Diagn Pathol 2012, 7-53.
Rulla M. Tamimi, Bernard Rosner, Graham Colditz. Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion. Cancer, 2010 November 1; 116(21):4944-4953.
Kristina M. Blackmore, Jody Wong, Julia A. Knight. A cross sectional study of different patterns of oral contraceptive use among premenopausal woman and circulatin IGF-1: implications for disease risk. BMC Womens Health, 2011, 11-15.
Habánová M, Svikruhová J, Sláviková E. Hormonal contraceptives and their relationship to breast cancer. Klin Onkol. 2010;23(6):428-32.
Lynn Rosenberg, Yuging Zhang, Patricia F. Coogan, Brian L. Strom, Julie R. Palmer. A Case-Control Study of Oral Contraceptive Use and Incident Breast Cancer. Am J Epidemiol 2009 February 15; 169(4): 473–479.
Lori C.Sakoda, Christie R.Blackston, Jennifer A. Doherty, Roberta M. Ray, Ming Gang Lin, Dao Li Gao, Helge Stasberg, Ziding Feng, David B. Thomas, Chu Chen. Selected estrogen receptor 1and androgen receptor gene polymorphisms in relation to risk of breast cancer and fibrocystic breast conditions among Chinese women. Cancer Epidemiol, 2011 February 35(1): 48-55.
Lynn Rosenberg, Deborah A. Boggs, Lauren A.Wise, Lucile L.Adams-Campbell, Julie R. Palmer. Oral contraceptive useand estrogen/progesterone receptor negative breast cancer among African American Women. Cancer Epidemiol Biomarkers Prev. 2010 August; 19(8): 2073-2079.
Marchbanks PA, Curtis KM, Mandel MG, et all. Oral contraceptive formulation and risk of breast cancer. Contraception. 2012 Apr;85(4):342-50. Epub 2011 Sep 28.
Hunter DJ, Colditz GA, Hankinson SE, et all. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2496-502.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186